EP 0711345 A1 19960515 - B7-2: CTL A4/CD 28 COUNTER RECEPTOR
Title (en)
B7-2: CTL A4/CD 28 COUNTER RECEPTOR
Title (de)
B7-2: CTL A4/CD 28 "GEGEN REZEPTER"
Title (fr)
B7-2: CONTRE-RECEPTEUR DE CTL A4/CD 28
Publication
Application
Priority
- US 10162493 A 19930726
- US 10939393 A 19930819
- US 14777393 A 19931103
- US 9408423 W 19940726
Abstract (en)
[origin: WO9503408A1] Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in Figure 8, SEQ ID NO: 1 or Figure 14, SEQ ID NO: 23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.
IPC 1-7
C12N 15/12; C07K 14/705; C07K 16/28; C12N 5/10; C12N 15/62; A61K 35/12; A61K 38/17; A01K 67/027; G01N 33/68
IPC 8 full level
A01K 67/027 (2006.01); A61K 35/12 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07H 21/04 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01); C12N 5/24 (2006.01); C12N 15/02 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); C12P 21/02 (2006.01); C12Q 1/02 (2006.01); G01N 33/566 (2006.01); G01N 33/68 (2006.01); C12R 1/91 (2006.01)
CPC (source: EP)
A61P 31/12 (2017.12); A61P 31/18 (2017.12); A61P 35/00 (2017.12); A61P 37/00 (2017.12); A61P 37/02 (2017.12); A61P 37/04 (2017.12); A61P 37/06 (2017.12); A61P 37/08 (2017.12); A61P 43/00 (2017.12); C07K 14/70532 (2013.01); C07K 16/2827 (2013.01); C12N 15/8509 (2013.01); A01K 2207/15 (2013.01); A01K 2217/00 (2013.01); A01K 2217/05 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0381 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)
Citation (search report)
See references of WO 9503408A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9503408 A1 19950202; AU 7405294 A 19950220; AU 9699198 A 19990218; CA 2167091 A1 19950202; EP 0711345 A1 19960515; JP 2009060905 A 20090326; JP H09500788 A 19970128
DOCDB simple family (application)
US 9408423 W 19940726; AU 7405294 A 19940726; AU 9699198 A 19981208; CA 2167091 A 19940726; EP 94924017 A 19940726; JP 2008237969 A 20080917; JP 50539795 A 19940726